top of page
Our Pipeline
Skyhawk develops a broad portfolio of small molecule RNA-modifying drug candidates that have the potential to improve the lives of patients by directly addressing the causes of disease.
Our wholly-owned pipeline includes programs across neurodegenerative, oncology, neuromuscular, fibrotic diseases, and other disease types. Many of our programs address targets formerly considered “undruggable” for traditional protein-targeting mechanisms.
Huntington's Disease
SKY-0515
HTT
Small molecule splicing modulator
Phase 3
Discovery
Preclinical
Phase 1
Phase 2
Target
Platform
Product Candidate
Multiple Myeloma,
Non-Hodgkin’s
Lymphoma
SKY-1214
FANCL/
FANCI
Small molecule splicing modulator
Neurology
SKY-1300
Undisclosed
Small molecule splicing modulator
Neurology
SKY-1500
Small molecule splicing modulator
Undisclosed
Oncology
SKY-1800
Undisclosed
Small molecule splicing modulator
Fibrosis
SKY-1700
Undisclosed
Small molecule splicing modulator
Indication
Owner
Oncology Assets
Neurology Assets
Fibrotic Disease Assets
Partnered Pipeline
Our confidential partnered pipeline with major Pharma includes over a dozen preclinical programs
across neurodegenerative, oncology, neuromuscular, rare and other disease types.
bottom of page